Business briefs: Endo; Allergan

Share this article:

Endo, which has been reportedly on the hunt for a buyer, named former Valeant president Rajiv De Silva president and CEO, effective March 18. The company's C-Suite shakeup has given a boost to its stock price, which hit its highest point since January 30, reported Bloomberg.

Allergan has settled a Botox-related lawsuit in Oklahoma  for an undisclosed amount, according to Bloomberg. The company was sued by the mother of a teenager who claimed the treatment, used for a leg condition, in this case, led to his death. She also alleged Allergan “promoted the drug for children despite a lack of regulatory approval for such use." This is not the first time the company has been accused of marketing the drug for unapproved uses—as Pharmalot noted in June, the company paid $600 million three years ago for off-label promotion.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.